» Articles » PMID: 33440782

Venous Thrombosis and Thrombocyte Activity in Zebrafish Models of Quantitative and Qualitative Fibrinogen Disorders

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 14
PMID 33440782
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Venous thrombosis occurs in patients with quantitative and qualitative fibrinogen disorders. Injury-induced thrombosis in zebrafish larvae has been used to model human coagulopathies. We aimed to determine whether zebrafish models of afibrinogenemia and dysfibrinogenemia have different thrombotic phenotypes. Laser injuries were used to induce venous thrombosis and the time-to-occlusion (TTO) and the binding and aggregation of fluorescent thrombocytes measured. The larvae failed to support occlusive venous thrombosis and showed reduced thrombocyte binding and aggregation at injury sites. The larvae were largely unaffected. When genome editing zebrafish to produce fibrinogen Aα R28C, equivalent to the human Aα R35C dysfibrinogenemia mutation, we detected in-frame skipping of exon 2 in the fga mRNA, thereby encoding Aα. This mutation is similar to Fibrinogen Montpellier II which causes hypodysfibrinogenemia. Aα fish had prolonged TTO and reduced thrombocyte activity, a dominant effect of the mutation. Finally, we used transgenic expression of fga R28C cDNA in fga knock-down or mutants to model thrombosis in dysfibrinogenemia. Aα R28C expression had similar effects on TTO and thrombocyte activity as Aα. We conclude that thrombosis assays in larval zebrafish can distinguish between quantitative and qualitative fibrinogen disorder models and may assist in anticipating a thrombotic phenotype of novel fibrinogen mutations.

Citing Articles

The utility of zebrafish thrombosis models in determining the location of thrombus formation.

Chowdhury D Ann Transl Med. 2023; 11(10):335.

PMID: 37675325 PMC: 10477636. DOI: 10.21037/atm-23-1667.


Fishing for answers to hemostatic and thrombotic disease: Genome editing in zebrafish.

Raghunath A, Ferguson A, Shavit J Res Pract Thromb Haemost. 2022; 6(5):e12759.

PMID: 35949884 PMC: 9354590. DOI: 10.1002/rth2.12759.


Role of Neutrophils and NETs in Animal Models of Thrombosis.

Carminita E, Crescence L, Panicot-Dubois L, Dubois C Int J Mol Sci. 2022; 23(3).

PMID: 35163333 PMC: 8836215. DOI: 10.3390/ijms23031411.


High Mutational Heterogeneity, and New Mutations in the Human Coagulation Factor V Gene. Future Perspectives for Factor V Deficiency Using Recombinant and Advanced Therapies.

Bernal S, Pelaez I, Alias L, Baena M, De Pablo-Moreno J, Serrano L Int J Mol Sci. 2021; 22(18).

PMID: 34575869 PMC: 8465496. DOI: 10.3390/ijms22189705.

References
1.
Mosesson M . Update on antithrombin I (fibrin). Thromb Haemost. 2007; 98(1):105-8. View

2.
Tajdar M, Orlando C, Casini A, Herpol M, De Bisschop B, Govaert P . Heterozygous FGA p.Asp473Ter (fibrinogen Nieuwegein) presenting as antepartum cerebral thrombosis. Thromb Res. 2017; 163:185-189. DOI: 10.1016/j.thromres.2017.10.020. View

3.
Jagadeeswaran P, Liu Y . A hemophilia model in zebrafish: analysis of hemostasis. Blood Cells Mol Dis. 1997; 23(1):52-7. DOI: 10.1006/bcmd.1997.0118. View

4.
Flood V, Nagaswami C, Chernysh I, Al-Mondhiry H, Weisel J, Farrell D . Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability. Br J Haematol. 2007; 138(1):117-24. DOI: 10.1111/j.1365-2141.2007.06630.x. View

5.
Ariens R . Fibrin(ogen) and thrombotic disease. J Thromb Haemost. 2013; 11 Suppl 1:294-305. DOI: 10.1111/jth.12229. View